HR. 6509In Committee
SAFE Drugs Act of 2025
Increase oversight of drug compounding by limiting when compounded drugs can copy commercially available drugs and by requiring reporting and inspection for higher-volume compounding
Plain-English overview
What this bill does
Increase oversight of drug compounding by limiting when compounded drugs can copy commercially available drugs and by requiring reporting and inspection for higher-volume compounding
Key points
- Require annual compounding reports
- Direct regular facility inspections
- Modify copy drug standard
- Increase monthly compounding limit
Current status
Where it stands
Status
In Committee
Latest action
2025-12-09 — Referred to the House Committee on Energy and Commerce.
Related context
Topics and policy areas
undefinedHealth